Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in St. Ingbert – page 10

306 clinical trials in St. Ingbert, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
St. Ingbert at a glance
306
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

306 trials in St. Ingbert

Open in trial search

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1206
  • Sponsor:BioInvent International AB

Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:GBG Forschungs GmbH

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in St. Ingbert

What the registry says about research in the country

01 Cardiovascular Diseases

In St. Ingbert-Oberwürzbach, clinical research in cardiovascular diseases is focused on reducing heart-related risk and improving long-term outcomes for people with atherosclerotic cardiovascular disease and broader cardiovascular disease concerns.

  • Studies on protecting against major cardiovascular events such as heart attack and stroke
  • Research evaluating whether new treatments can lower cardiovascular risk alongside standard care
  • Trials examining cholesterol control in people with established heart and blood vessel disease

These trials aim to test whether newer therapies can improve prevention and treatment effectiveness in everyday care.

02 Nutritional and Metabolic Diseases

A second major research area is nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes.

  • Weight management studies for people living with obesity or excess body weight
  • Trials combining diabetes care with efforts to support healthier weight outcomes
  • Research looking at better approaches for long-term metabolic control

The overall goal is to explore treatments that can help people lose weight, maintain results, and reduce related health risks.

03 Diabetes and Glycaemic Control

Several studies are centered on diabetes, including type 1 diabetes and type 2 diabetes mellitus, with attention to improving blood sugar control and related complications.

  • Trials comparing new insulin strategies for people with type 1 diabetes
  • Research on glucose-lowering treatments for patients with type 2 diabetes and cardiovascular risk
  • Studies assessing the broader impact of diabetes therapies on long-term health

This work is designed to see whether newer treatment approaches can offer better control and support safer diabetes management.

04 Obesity and Weight Management

A large share of the local trial activity involves obesity and chronic weight management, reflecting strong interest in therapies that support meaningful and lasting weight reduction.

  • Studies testing new medicines for adults with obesity or overweight
  • Research focused on maintaining weight loss over time
  • Trials examining how weight reduction may also improve related metabolic health

These studies are intended to better understand how treatment can support healthier body weight and reduce associated complications.

05 Lipid Lowering and Cardiometabolic Risk

Some trials in Germany are investigating whether newer lipid-lowering approaches can better manage hypercholesterolemia and lower the risk of future heart problems.

  • Research comparing cholesterol-lowering options in people with cardiovascular disease
  • Studies assessing added benefit alongside standard treatment
  • Trials aimed at improving prevention of heart and vascular events

The focus is on finding more effective ways to reduce harmful cholesterol and protect long-term cardiovascular health.

06 Eye Health in Diabetes

One notable study area examines diabetic retinopathy in people with type 2 diabetes, exploring whether diabetes treatment can influence eye health over time.

  • Safety-focused research on long-term effects for diabetic eye disease
  • Studies using ophthalmic assessments to monitor progression
  • Work aimed at understanding how improved glucose control may affect eye complications

This research supports a better understanding of how diabetes therapies may shape both blood sugar control and vision-related outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.